Streetbeat News

Analyst Ratings

HCA

Bernstein analyst Lance Wilkes downgraded HCA Healthcare (NYSE:HCA) from Outperform to Market Perform and set a price target of $301.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:51 pm

MBLY

B of A Securities analyst John Murphy has downgraded Mobileye Global (MBLY) from Neutral to Underperform and reduced the price target from $47 to $22.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:45 pm

MCD

Stifel analyst Chris O'Cull has maintained a Hold rating on McDonald's (NYSE:MCD) and increased the price target from $285 to $322.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:41 pm

EAT

Stifel analyst Chris O'Cull has reaffirmed a Buy rating on Brinker International (NYSE:EAT) and increased the price target from $45 to $50. This adjustment suggests a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:37 pm

ALL

Allstate's stock (ALL) is trading higher following an upgrade by Morgan Stanley from Equal-Weight to Overweight, with a price target increase from $117 to $171.

Portfolio Pulse from Bill Haddad

January 04, 2024 | 4:36 pm

DPZ

Stifel analyst Chris O'Cull has maintained a Buy rating on Domino's Pizza (NYSE:DPZ) and increased the price target from $440 to $470, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:32 pm

CMG

Stifel analyst Chris O'Cull has reaffirmed a Buy rating on Chipotle Mexican Grill (NYSE:CMG) and increased the price target from $2100 to $2450, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:31 pm

XRTX

XORTX Therapeutics shares have seen an increase in their trading value following an endorsement from Alliance Global Partners, which maintained a Buy rating and increased the price target for the stock from $9 to $14.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:30 pm

IQV

Truist Securities analyst Jailendra Singh has reaffirmed a Buy rating on IQVIA Holdings (IQV) and increased the price target from $240 to $286.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:27 pm

COLL

Truist Securities analyst Gregg Gilbert has reaffirmed a Buy rating on Collegium Pharmaceutical (NASDAQ:COLL) and increased the price target from $31 to $37.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:26 pm